AlloCyte Pharmaceuticals

Pre-clinical

Basel, SwitzerlandFounded 2016allocyte-pharmaceuticals.com

AlloCyte Pharmaceuticals AG is a private, Swiss-based biotech focused on developing oral allosteric integrin modulators to protect tissue integrity by restoring natural immune balance in autoimmune diseases. The company's platform addresses the limitations of first-generation integrin therapies by avoiding paradoxical effects and broad immunosuppression. Its lead candidate is in late preclinical development, with a key milestone being clinical therapeutic proof-of-concept. The company leverages a strategic collaboration with a leading US academic clinical institution to validate its pharmacology in patient-derived materials.

Founded

2016

Focus

ImmunologyCell Therapy

AI Company Overview

Technology Platform

A proprietary platform for discovering oral small-molecule allosteric modulators of integrins, designed to recalibrate aberrant receptor activity and restore immune balance without the broad immunosuppressive or paradoxical effects of earlier integrin-targeted therapies.

Funding History

Total raised: $17M

Series A$8MVerve VenturesMar 15, 2023

Seed$6.5MUndisclosedApr 15, 2022

Seed$2.5MHigh-Tech GründerfondsJun 15, 2021

Opportunities

The primary opportunity is to revolutionize the treatment of severe autoimmune diseases by introducing an oral, precision therapy that restores immune balance rather than causing broad immunosuppression.

Success with the lead program would validate the allosteric integrin platform, unlocking its application across a wide range of high-value indications including fibrosis, cancer, and neurodegenerative diseases.

Risk Factors

Key risks include the inherent uncertainty of preclinical and clinical development for a novel mechanism, the scientific risk that allosteric recalibration may not translate to human disease as hypothesized, and the financial risk associated with a private, pre-revenue company dependent on future fundraising.

Intense competition in the autoimmune space also poses a commercial threat.

Competitive Landscape

AlloCyte competes against first-generation integrin inhibitors (e.g., vedolizumab, natalizumab) and the broader landscape of autoimmune therapies. Its main differentiation is the combination of an oral allosteric mechanism designed for precise immune recalibration, aiming to avoid the limitations of IV-administered biologics and small-molecule ligand mimetics that can cause broad immunosuppression or paradoxical effects.